• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?

作者信息

Black-Maier Eric, Piccini Jonathan P

机构信息

Duke Center for Atrial Fibrillation, Duke University Medical Center, Durham, North Carolina, USA.

Duke Clinical Research Institute, Durham, North Carolina, USA.

出版信息

Heart. 2017 Jun;103(11):807-808. doi: 10.1136/heartjnl-2016-310540. Epub 2017 Jan 9.

DOI:10.1136/heartjnl-2016-310540
PMID:28069637
Abstract
摘要

相似文献

1
Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?终末期肾病合并心房颤动的口服抗凝治疗：是时候对药物说“不”了吗？
Heart. 2017 Jun;103(11):807-808. doi: 10.1136/heartjnl-2016-310540. Epub 2017 Jan 9.
2
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2.终末期肾病患者心房颤动管理中口服抗凝药的应用：裁决2
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2095-2096. doi: 10.2215/CJN.09470916. Epub 2016 Oct 25.
3
Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1.口服抗凝药在接受血液透析的终末期肾病合并心房颤动患者中的应用：结论1
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2093-2094. doi: 10.2215/CJN.08610816. Epub 2016 Oct 25.
4
Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response.心房颤动合并终末期肾病患者口服抗凝治疗的应用：当下需要什么？回应。
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):97-98. doi: 10.1016/j.rec.2018.08.002. Epub 2018 Aug 31.
5
Use of Oral Anticoagulation for Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays?心房颤动合并终末期肾病患者口服抗凝治疗的应用：当下需要什么？
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):96-97. doi: 10.1016/j.rec.2018.07.007. Epub 2018 Aug 17.
6
Stroke prevention in atrial fibrillation patients with chronic kidney disease.房颤合并慢性肾脏病患者的卒中预防。
Can J Cardiol. 2013 Jul;29(7 Suppl):S71-8. doi: 10.1016/j.cjca.2013.04.005.
7
Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation.老年房颤患者抗凝治疗的禁忌证及新型抗凝剂的适用情况
Cardiovasc Ther. 2015 Aug;33(4):177-83. doi: 10.1111/1755-5922.12129.
8
[Anticoagulation for stroke prevention in atrial fibrillation - new concepts, new challenges].[心房颤动卒中预防的抗凝治疗——新概念、新挑战]
MMW Fortschr Med. 2018 Nov;160(Suppl 3):34-38. doi: 10.1007/s15006-018-1118-4.
9
Oral anticoagulation for elderly patients with non-valvular atrial fibrillation: recent insights from randomised trials and the 'real world'.老年非瓣膜性心房颤动患者的口服抗凝治疗：随机试验及“真实世界”的最新见解
Heart. 2017 Jul;103(13):977-978. doi: 10.1136/heartjnl-2017-311162. Epub 2017 Mar 3.
10
Anticoagulation in atrial fibrillation and chronic heart failure: the risk and drug of choice.心房颤动与慢性心力衰竭的抗凝治疗：风险与首选药物
Curr Opin Cardiol. 2016 Mar;31(2):229-34. doi: 10.1097/HCO.0000000000000245.

引用本文的文献

1
Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?肝硬化患者的抗凝治疗：是敌是友？
Dig Dis Sci. 2023 Jun;68(6):2237-2246. doi: 10.1007/s10620-023-07858-9. Epub 2023 Mar 24.
2
Triazol-1-yl Benzamides Promote Anticoagulant Activity Inhibition of Factor XIIa.三唑基苯甲酰胺促进抗凝活性 抑制因子 XIIa。
Cardiovasc Hematol Agents Med Chem. 2023;21(2):108-119. doi: 10.2174/1871525721666221031141323.
3
Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.磺化非糖分子与人类因子 XIa：酶抑制和计算研究。
Chem Biol Drug Des. 2022 Jul;100(1):64-79. doi: 10.1111/cbdd.14053. Epub 2022 Apr 11.
4
Factor IX(a) inhibitors: an updated patent review (2003-present).因子 IX(a)抑制剂：更新的专利审查（2003 年至今）。
Expert Opin Ther Pat. 2022 Apr;32(4):381-400. doi: 10.1080/13543776.2022.2026926. Epub 2022 Jan 17.
5
Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa.木质素磺酸钠是人类凝血因子XIa的非竞争性抑制剂。
Pharmaceuticals (Basel). 2021 Aug 31;14(9):886. doi: 10.3390/ph14090886.
6
Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia.发现苯甲基四膦酸衍生物作为人因子 Xia 的抑制剂。
ChemistryOpen. 2020 Nov 10;9(11):1161-1172. doi: 10.1002/open.202000277. eCollection 2020 Nov.
7
Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).因子 XI(a)抑制剂治疗血栓：更新的专利审查（2016 年至今）。
Expert Opin Ther Pat. 2020 Jan;30(1):39-55. doi: 10.1080/13543776.2020.1705783. Epub 2019 Dec 19.
8
Contemporary management and outcomes of infective tunnelled haemodialysis catheter-related right atrial thrombi: a case series and literature review.经皮隧道式血液透析导管相关右心房血栓的当代治疗和结局：病例系列和文献复习。
Singapore Med J. 2020 Jun;61(6):331-337. doi: 10.11622/smedj.2019124. Epub 2019 Oct 8.
9
Left atrial deformation as a potent predictor for paroxysmal atrial fibrillation in patients with end-stage renal disease.左心房变形作为终末期肾病患者阵发性心房颤动的有力预测指标。
Int J Cardiovasc Imaging. 2018 Sep;34(9):1393-1401. doi: 10.1007/s10554-018-1353-x. Epub 2018 Apr 21.